bioRxivMicrobiologyPreprint
Potent Neutralizing Activity of Polyclonal Equine Antibodies against Omicron SARS-CoV-2
J. Luczkowiak, P. Radreau, L. Nguyen, N. Labiod, F. Lasala, C. H. Herbreteau, R. Delgado
Abstract
Using a polyclonal approach of equine anti-SARS-CoV-2 F(ab)2 antibodies we have achieved a high level of neutralizing potency against all SARS-CoV-2 variants tested. Neutralization titers were in the range of 105-106 IU/mL including Omicron: 111,403 UI/mL, which is 2-3 orders of magnitude what is normally achieved in response to SARS-CoV-2 infection and/or vaccination. The presence of high titers of a repertoire of antibodies targeting conserved epitopes in different regions of the spike protein could plausibly account for this remarkable breadth of neutralization. These results warrant the clinical investigation of anti-SARS-CoV-2 equine polyclonal F(ab)2 antibodies as a novel therapeutic strategy against COVID-19
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development of Equine Polyclonal Antibodies as a Broad-Spectrum Therapy Against SARS-CoV-2 Variants
- High efficacy of therapeutic equine hyperimmune antibodies against SARS CoV-2 variants of concern
A. Moreira-Soto, M. Arguedas, … J. F. Drexler·bioRxiv·Jun 12, 2021
- Development of Equine Immunoglobulin Fragment F(ab')2 with High Neutralizing Capability against SARS-CoV-2
D. Gupta, F. Ahmed, … K. H. Harshan·bioRxiv·Mar 9, 2021
- Potent neutralizing equine antibodies raised against recombinant SARS-CoV-2 spike protein for COVID-19 passive immunization therapy
L. E. R. Cunha, A. A. Stolet, … J. L. Silva·bioRxiv·Aug 17, 2020
- Development and pre-clinical characterization of two therapeutic equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19
G. Leon, M. Herrera, … A. Alape·bioRxiv·Oct 17, 2020
- Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
D. J. Sheward, C. Kim, … B. Murrell·bioRxiv·Dec 19, 2021